Vycor Medical, Inc. ("Vycor") (OTCBB: VYCO), a medical device
company with a suite of FDA cleared products, announced today it
has been granted Japanese patent #JP5068770 for its NovaVision®
technology. The patent covers methods for performing vision therapy
by stimulating regions of the patient's field of vision that are
technically "blind," but may still respond positively to repeated
stimulus to eventually improve or recover vision in the blind
field.
The claims complement other issued patents surrounding
NovaVision's therapeutic methods that utilize stimulation in
transitional zones of deteriorated vision. The new patent brings
Vycor's worldwide total patent portfolio for NovaVision to 30
granted and 9 pending.
Vycor's wholly-owned NovaVision subsidiary is the worldwide
leader in the field of vision rehabilitation and the largest such
provider by far in the U.S., Europe, and other global markets.
NovaVision's VRT™ is the only medical device aimed at the
restoration of vision for neurologically induced vision loss which
has FDA 510 (K) clearance to be marketed in the U.S.
NovaVision develops and markets a non-invasive, computer-based
light stimulation therapy called Vision Restoration Therapy (VRT™)
and through its recently acquired subsidiary, Sight Science, a
similar therapy called Neuro-Eye Therapy (NeET). Both therapies are
aimed at those suffering from vision loss resulting from
neurological trauma such as stroke and traumatic brain injury
(TBI). The therapies are not dependent upon how long ago
neurological trauma occurred.
According to the U.S. Centers for Disease Control (CDC) and the
American Heart Association, there are an estimated 8 million
Americans who have previously had a stroke incident, with 740,000
additional cases occurring annually. Additionally, approximately
5.3 million Americans live with long-term deficits resulting from a
traumatic brain injury (TBI). These numbers and rate of growth are
only expected to accelerate as our populations' age profile
increases. It is estimated that approximately 30% of these stroke
and TBI victims experience some sort of visual impediments as a
result of their ailment. While many of these individuals do improve
naturally, the consensus across most studies indicates
approximately 16% experience permanent visual field deficits -- a
finding consistent with the Company's experience. It is this 16%
with permanent visual field deficits that VRT addresses.
Given available information and the Company's experience to
date, management estimates NovaVision's addressable target market
for VRT (both stroke and TBI victims suitable for therapy) to be
nearly 1.5 million individuals in the U.S., approximately 1.4
million people in Europe, and approximately 6.4 million throughout
the rest of the world. The U.S. and EU alone represent a total
addressable market size in excess of $2.6 billion, and when
expanded worldwide the total market potential exceeds $8
billion.
While speech, physical, and occupational therapies are the
long-standing treatment standards for stroke and TBI survivors, VRT
is the first and only FDA-cleared clinical component of vision
restoration to physically enhance the visual field after a stroke
or TBI.
VRT is a patient-specific diagnostic and therapeutic platform
with extensive clinical data supporting its ability to increase a
patient's visual field by an average of 5 degrees -- a significant
improvement since visual functionality largely depends on the
central 10 degrees of one's sight. The therapy is delivered
currently through a computer in the patient's home. To date, over
2,000 patients have been treated with VRT and over 100 patients
with NeET.
Commenting on the Company's progress, David Cantor, President of
Vycor, stated, "We continue to be very excited by the potential we
see for NovaVision and our excitement is further underpinned by
continued positive patient testimonials. We are currently focused
on some key strategic development projects that are underway which
we believe will help ensure NovaVision becomes the 'Gold Standard'
for the rehabilitation and restoration of vision loss resulting
from neurological trauma."
About Vycor Medical, Inc.
With corporate headquarters in Boca Raton, FL, Vycor Medical,
Inc. ("Vycor") is a publicly traded company (OTCBB: VYCO) dedicated
to providing the medical community with innovative and superior
surgical and therapeutic solutions and has a growing portfolio of
FDA-cleared medical solutions that are changing and improving lives
every day. The Company operates two business units: Vycor Medical
and NovaVision, both of which adopt a minimally or non-invasive
approach. Both technologies have exceptional sales growth
potential, address large potential markets, have the requisite
regulatory approvals and are commercialized and generating revenue.
The Company has a strong patent portfolio with 36 granted patents
and a further 19 patents pending.
Vycor Medical's flagship, ViewSite™ Surgical Access Systems
(VBAS), is a suite of clear cylindrical minimally invasive
disposable devices that hold the potential for speedier, safer and
more economical brain surgeries and a quicker patient discharge.
VBAS is designed to optimize neurosurgical site access, reduce
patient risk, accelerate recovery and add tangible value to the
professional medical community. Vycor Medical is ISO 13485:2003
compliant, has FDA 510(K) clearance for VBAS for brain and spine
surgeries and regulatory approvals for brain surgeries in
Australia, Canada, China, Europe, Japan, Korea and Russia. For an
overview of Vycor Medical's VBAS see
http://player.vimeo.com/video/39766887
NovaVision develops and provides science-driven neurostimulation
therapy and other medical technologies that help improve and
partially restore sight in patients with neurological vision
impairments. The company's proprietary Visual Restoration Therapy®
(VRT) platform is clinically supported to improve lost vision
resulting from stroke, traumatic brain injury ("TBI"), or other
acquired brain injuries. VRT is the only FDA 510(K) cleared medical
device in the U.S. aimed at the restoration of vision for
neurologically induced vision loss and can be prescribed by any
ophthalmologist, optometrist, neurologist or physiatrist. VRT also
has CE Marking for the EU. NovaVision also provides Neuro-Eye
Therapy (NeET) in the EU, aimed at increasing visual sensitivity
deep within the field defect. NovaVision also provides a fully
portable and ADA-compliant Head Mounted Perimeter (HMP™) which aids
in the detection and measurement of visual field deficits. For an
overview of NovaVision see
http://player.vimeo.com/video/39765566
For the latest information on the company, including media and
other coverage, and to learn more, please go online at
www.vycormedical.com or www.novavision.com.
Safe Harbor Statement
Information in this document constitute
forward-looking statements or statements which may be deemed or
construed to be forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. The words
"forecast," "anticipate," "estimate," "project," "intend," "expect,"
"should," "believe," and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements involve, and are subject to known and unknown risks,
uncertainties and other factors which could cause Vycor Medical's
actual results, performance (financial or operating) or
achievements to differ from the future results, performance
(financial or operating) or achievements expressed or implied by
such forward-looking statements. The risks, uncertainties and other
factors are more fully discussed in Vycor Medical's filings with
the U.S. Securities and Exchange Commission. All forward-looking
statements attributable to Vycor Medical herein are expressly
qualified in their entirety by the above-mentioned cautionary
statement. Vycor Medical disclaims any obligation to update
forward-looking statements contained in this estimate, except as
may be required by law.
Vycor Medical, Inc Investor Contacts: The Del Mar Consulting
Group, Inc. Robert B. Prag President 858-794-9500 Email Contact or
Alex Partners, LLC Scott Wilfong President 425- 242-0891 Email
Contact
Vycor Medical (QB) (USOTC:VYCO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vycor Medical (QB) (USOTC:VYCO)
Historical Stock Chart
From Jul 2023 to Jul 2024